Purpose The aim of this study was to review the evidence on the epidemiology, physiopathology, categorization, and management of cholinergic urticaria. We specifically focused on several subtypes of cholinergic urticaria and investigated the relationship between cholinergic urticaria and idiopathic anhidrosis. Methods Using an integrative approach, we reviewed publications addressing the epidemiology, clinical features, diagnostic approach, physiopathology, subtype classification, and therapeutic approach to cholinergic urticaria. Results Multiple mechanisms were found to contribute to the development of cholinergic urticaria. This disorder should be classified based on the pathogenesis and clinical characteristics of each subtype. Such a classification system would lead to better management of this resistant condition. In particular, sweating function should be given more attention when examining patients with cholinergic urticaria. Conclusions Because cholinergic urticaria is not a homogeneous disease, its subtype classification is essential for selection of the most suitable therapeutic method.
Introduction
Cholinergic urticaria (CholU), first described by Duke [1] in 1924, is a frequently occurring skin disorder characterized by unique clinical features. Pinpoint, highly pruritic wheals with surrounding erythema appear after sweating induced by an increase in the core body temperature, which occurs in response to hot bathing, physical exercise, and/or emotional stress [2, 3] . Although the symptoms usually subside rapidly, commonly within 1 h, most patients with CholU complain that they feel stinging or tingling pain and/or itching at the onset of symptoms, and these feelings appear to disturb their quality of life [4, 5] . Severe symptoms such as angioedema, respiratory symptoms, and/or anaphylaxis often accompany CholU [2, 4, [6] [7] [8] . Although CholU affects up to 20% of young adults, the precise underlying mechanism of the whealing response remains unclear, with the exception of the involvement of acetylcholine, poral occlusion, cholinergic receptor M3 (CHRM3), sweat allergy, serum factors, and dyshidrosis [9] [10] [11] . We and other research groups recently proposed four subtypes of CholU based on the pathogenesis and clinical characteristics of this condition: (1) conventional sweat allergy-type CholU, (2) follicular-type CholU with a positive autologous serum skin test (ASST) result, (3) CholU with palpebral angioedema (CholU-PA), and (4) CholU with acquired anhidrosis and/or hypohidrosis [9, [12] [13] [14] [15] [16] . The European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network (GA 2 
LEN)/European Dermatology Forum (EDF)/ Urticaria Network e.V. (UNEV) recommend defining
CholU as a subtype of chronic inducible urticaria [17] . The disorder should be treated as a physical urticaria/angioedema syndrome according to the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology [18] . CholU is classified as inducible urticaria in the Japanese Dermatological Association guidelines for the diagnosis and treatment of urticaria [19] .
In the present review, we focus on the classification of CholU, especially with respect to the relationship between CholU and sweating function, and present an overview of the current knowledge of the pathogenesis of the disorder and therapeutic methods.
Clinical features, provocation test, and differential diagnosis of CholU Clinical features
CholU is characterized by the development of numerous distinct small hives, usually 1-3 mm in diameter, with red halos (Fig. 1) . However, these hives may occasionally become larger in size and coalesce with one another (Fig. 1) . The eruptions can occur anywhere on the body except for the palms, soles, and axillae, but the most commonly affected part of the body is the trunk [2, 3, 11] . Because active or passive warming leads to the development of pinpoint wheals and itching, the symptoms rarely occur at bedtime. In contrast to other types of urticaria, many patients with CholU complain that they feel stinging or tingling pain but no itching. Severe symptoms such as angioedema, respiratory distress, dizziness, and/or anaphylaxis often accompany the disease. Although the prevalence of CholU does not generally show a large sexrelated difference, serious symptoms including anaphylaxis seem to occur more frequently in female patients [8, 13, 14] . Most patients' symptoms become more pronounced in hot summer weather, although some patients exhibit exacerbation during exercise and bathing in cold weather [20] . CholU is most common in the second and third decades of life [2, 11] , with an estimated prevalence of 4. 16-11.2% in the general population [11, 21] . It is frequently associated with atopic diathesis including atopic dermatitis, allergic rhinitis, and bronchial asthma [13, 22, 23] . Patients with moderate to severe CholU seem to show high rates of atopy [13, 23] .
Provocation test
Because the symptoms of CholU develop only after an increase in body temperature has been stimulated in a repetitive manner, and given the characteristic appearance of the eruptions, the clinical diagnosis of CholU is usually not difficult. However, a provocation test should be performed to confirm the diagnosis and to rule out other types of urticaria. Provocation tests for the diagnosis of CholU are performed by increasing the body temperature through exercise (treadmill or stationary bicycle) or the use of a hot bath (42°C for 15 min) [24] [25] [26] . The EAACI/GA 2 LEN/ EDF/UNEV consensus panel recommends the following diagnostic criterion for confirmation of CholU: an increase in core body temperature [1.0°C over baseline as indicated by a passive warming test involving sitting for up to 15 min in a full water bath at 42°C [17, 24] . However, the problem associated with this test is the inaccuracy of body temperature measurement. Although an esophageal or rectal thermometer is more accurate than an oral thermometer, the former is invasive and unsuitable for outpatients. Therefore, a standardized protocol for diagnosing and measuring CholU thresholds using pulse-controlled ergometry has been proposed [27] . Interestingly, pulsecontrolled ergometry has demonstrated that the critical trigger in the development of CholU is sweating rather than a rise in the mean body temperature. Intradermal injection of cholinergic drugs such as acetylcholine or methacholine may produce small satellite wheals surrounding the injection site in certain patients with CholU ( Fig. 2) [14, 26] . Because this examination is not necessarily positive in all patients with CholU, it is used as a supplementary test for the diagnosis of CholU. One advantage is that local sweating function can be simultaneously observed by intradermal injection of cholinergic drugs such as acetylcholine [14, 28] .
Differential diagnosis
Based on whether the clinical episode has developed secondary to exercise and/or heat stimulation, CholU Fig. 1 a Typical appearance of cholinergic urticaria: pinpoint-sized, highly pruritic wheals with surrounding erythema occur on the trunk after sweating. b Occasionally, the wheals become larger in size and coalesce with one another must be differentiated from food-dependent exercise-induced anaphylaxis (FDEIA) and heat urticaria (HU). FDEIA is a unique form of food allergy induced by exercise after food ingestion [29] . FDEIA, in which symptoms do not appear without ingestion of food, and which usually involves a specific IgE antibody against causative food allergens, is clearly distinguishable from CholU. Skin prick tests, measurement of specific IgE, and provocation tests including challenges with the suspected foods, exercise, and aspirin intake, as well as combinations of these challenges, are valuable for differentiating between CholU and FDEIA. HU is defined by the appearance of wheals after contact heating of the skin within minutes of exposure. Localized HU is characterized by itchy erythema and well-demarcated wheals restricted to the heated area (Fig. 3) [30, 31] . The diagnosis of HU is confirmed by a heat provocation test involving the placement of metal/glass cylinders filled with hot water (Fig. 3) . Localized HU can be differentiated from CholU by the characteristic clinical signs that develop after provocation.
Because many types of stimulation can result in the development of similar clinical appearance, CholU should be differentiated from aquagenic urticaria, adrenergic urticaria, and cold-induced CholU. Aquagenic urticaria is a rare form of urticaria in which contact with any source of water at any temperature evokes small pruritic wheals surrounded by flare [32] . Diagnosis of aquagenic urticaria should be differentiated from other types of urticaria including CholU, cold urticaria, and HU before testing for aquagenic urticaria. Adrenergic urticaria is a rare type of stress-induced physical urticaria characterized by widespread pruritic urticarial papules [33] . Although the clinical picture of adrenergic urticaria resembles that of CholU, it can be distinguished from CholU by the presence of a white halo of vasoconstriction surrounding small red or pink wheals [34] . Diagnosis can be made by intradermal injection of adrenaline or noradrenaline, which produces the characteristic rash [35] . A positive noradrenaline test result and negative acetylcholine skin test result are useful for the differential diagnosis of adrenergic urticaria and CholU [35] . In cold-induced CholU (generalized reflex cold urticaria), widespread wheals occur in response to cooling of the core body temperature [6, 25] . Cold-induced CholU is an unusual disorder, characterized by small pinpoint urticarial lesions induced by a systemic rather than local cold challenge [28] .
The diagnostic workup in CholU is summarized in Fig. 4 .
Pathogenesis
Although the physiopathological mechanism of CholU has not been clearly defined, it is thought that histamine, cholinergic agents (e.g., acetylcholine), sweat allergy, serum factors, poral occlusion, and anhidrosis are related to the development of symptoms [14, [36] [37] [38] [39] .
Histamine
Previous studies have shown that the serum histamine level increases during the development of symptoms and after exercise in patients with CholU [37, 40] . Second-generation non-sedating histamine H1 receptor antagonists (H1RAs) are recommended as first-line therapy in patients with CholU; however, in contrast to patients with conventional urticaria, some patients with CholU do not respond to standard H1RA therapy [4, 10, 17, 41] . H1RA up-dosing in patients with CholU refractory to standard H1RA therapy has demonstrated limited effectiveness, with fewer than half of patients showing a substantial improvement in disease activity [41] . In one study, the addition of the histamine H2 receptor antagonist (H2RA) lafutidine to H1RA therapy reduced the itch severity, frequency of whealing, and size of the wheals [4] . These findings suggest that histamine plays an important role in the development of CholU, but that mediators other than histamine may also be closely associated.
Cholinergic agents
The sweat glands receive sympathetic innervation but express muscarinic acetylcholine receptors, which are normally expressed in the parasympathetic nervous system. Thus, stimulation of cholinergic postganglionic sympathetic nerves by acetylcholine is considered to be a central signal mediator of sweat secretion (Fig. 5 ) [10] . Intradermal injection of cholinergic agents can reproduce the symptoms of CholU, but not in all patients (Fig. 2 ) [14, 26] . Pilocarpine iontophoresis has been reported to induce wheals that are localized near the electrode. The acetylcholine antagonists atropine and scopolamine have been shown to inhibit the development of CholU in a minor population of patients with CholU. Thus, acetylcholine appears to play an essential role in the development of CholU. In fact, studies have demonstrated that not only sweat glands but also mast cells express CHRM3, which is responsible for the initiation of sweating [5, 15] . The authors of these papers proposed a schematic model in which acetylcholine released from postganglionic sympathetic nerves could not be trapped by the acetylcholine receptors of eccrine glands because of reduced expression of these receptors and overflow of acetylcholine to adjacent mast cells secondary to decreased expression of acetylcholine esterase. Although this schema is very interesting, this phenomenon is limited to the hypohidrotic area of CholU in patients with accompanying acquired generalized hypohidrosis, and does not apply to patients with CholU who have normal sweating function. In addition, this schema indicates that acetylcholine can ultimately activate mast cells and induce their degranulation in the hypohidrotic area of CholU. In our experience, however, H1RAs seem to be ineffective in inhibiting whealing formation in the hypohidrotic area of CholU (Fukunaga et al. unpublished data) . Furthermore, whether acetylcholine can induce the degradation of human mast cells in vivo remains controversial [5, 9] . Thus, although cholinergic agents are undoubtedly involved in the pathological mechanism of CholU, the detailed roles of these agents in its pathogenesis require further study.
Sweat allergy
Several studies have suggested the involvement of sweat allergy in the occurrence of CholU [14, [42] [43] [44] . In 1994, Adachi et al. [42] reported that patients with CholU showed positive immediate-type skin reactions and histamine release from basophils in response to contact with autologous diluted sweat. The same study demonstrated that after transfer of the patient's serum into a normal subject, skin tests with autologous sweat (autologous sweat skin test; ASwST) showed positive results, suggesting that these patients with CholU had a type I allergy to their own sweat.
In 2005, we reported that 11 of 17 patients with CholU showed immediate-type skin reactions, and confirmed that the level of histamine release from basophils in the response with autologous sweat correlated well with ASwST response [14] . In 2009, Takahagi et al. [22] demonstrated that 23 of 35 patients with CholU showed histamine release from basophils in response to semi- [45] identified a putative protein, MGL_1304 of Malassezia globosa, as a major allergen in human sweat of patients with atopic dermatitis. In another study, the concentrations of purified MGL_1304-specific IgE in the sera of patients with CholU were significantly higher than those of normal controls, and 14 of 24 patients with CholU were positive for purified MGL_1304-specific IgE [46] . These findings suggest that MGL_1304 in sweat is an important antigen in the majority of patients with CholU. A commercial histamine release test for MGL_1304 in sweat is available in Japan. We recently used this commercial histamine release test to detect sweat allergy in a characteristic case series of patients with CholU-PA [13] .
Serum factor
Half of patients with chronic spontaneous urticaria have IgG autoantibodies to FceRIa or FceRIa-bound IgE on dermal mast cells and basophils, which cross-link FceRI molecules to induce histamine release [47] . The ASST is useful for detecting these autologous serum factors [47, 48] . Sabroe et al. [48] reported that one in nine patients with CholU had a positive ASST result. Similarly, we previously showed a positive ASST result in 8 of 15 patients with CholU [14] . In our institution as well as others, one-third or fewer of all patients with CholU appear to have associated serum factors [49] .
Poral occlusion
Several reported cases indicate that CholU is caused by poral occlusion. Kobayashi et al. [39] showed that biopsy specimens from two patients with CholU and hypohidrosis exhibited occlusion of the superficial acrosyringium. The authors assumed that poral occlusion led to the leakage of sweat containing numerous inflammatory enzymes and cytokines, inducing local inflammation and lymphocytic inflammation around the upper sweat duct. They proposed that the occlusion and subsequent leakage of sweat from the sweat duct were responsible for the development of CholU accompanied by hypohidrosis. Rho [50] reported that the incidence of hypohidrosis in patients with CholUmost of whom complained of symptoms only in the winter season-was relatively high, and that topical application of anti-keratolytic agents to the affected area may be helpful. These reports suggest that poral occlusion is involved in the etiology of hypohidrotic CholU. We also described a patient with acquired idiopathic generalized anhidrosis (AIGA) accompanied by CholU, whose histopathology showed an occlusion of the superficial acrosyringium and infiltrates comprising lymphocytes and mast cells around the sweat glands [51] .
Hypohidrosis/anhidrosis
Previous studies have established that some patients with CholU have acquired generalized hypohidrosis/anhidrosis with various pathogeneses [38, 39, 52] . The etiologies include sweat gland or acetylcholine receptor autoimmunity, degeneration of post-ganglionic sympathetic skin nerve fibers, and poral occlusion (see above) [53, 54] . AIGA is a sweating disorder characterized by inadequate sweating in response to heat stimuli and is caused by sudomotor failure, which is probably a dysfunction on the postsynaptic side of the nerve-sweat gland junction [38] . With respect to hypohidrosis, approximately 30-60% of patients with AIGA show complications of CholU, also known as idiopathic pure sudomotor failure or hypohidrotic CholU. The relationship between CholU and anhidrosis is discussed in greater detail in the next section, which describes CholU subtype classification (see below).
Subtype classification
Four pathogenesis-and/or clinical feature-based subtypes of CholU were recently proposed: (1) conventional sweat allergy-type CholU without angioedema, (2) follicular-type CholU with a positive ASST result, (3) CholU-PA, and (4) CholU with acquired anhidrosis and/or hypohidrosis [10, 13, 14] . It is especially important to differentiate subtypes 1, 2, and 3 from subtype 4, particularly in terms of sweating function, because the clinical therapeutic approach appears to be very different. A thermoregulatory sweat test, drug-induced sweat test, quantitative sudomotor axon reflex test, and thermography should be used to evaluate sweat function [55] . The characteristics of the four subtypes of CholU are summarized in Table 1 .
Conventional sweat allergy-type CholU without angioedema
In 2005, we proposed a classification of CholU into two subtypes: (1) the sweat-hypersensitivity type (non-follicular type), which is characterized by non-follicular wheals, development of satellite wheals following local acetylcholine injection, a positive ASwST result, and lack of a positive ASST result; and (2) the follicular type, which is characterized by follicular wheals, lack of development of satellite wheals following local acetylcholine injection, and a positive ASST result [14, 49] . Indeed, generalized anhidrosis was comprehensively examined and excluded in that paper. However, we and other research groups have confirmed that almost all patients with CholU with anhidrosis or hypohidrosis, such as AIGA, lack sweat hypersensitivity [12, 16] . Thus, the sweat-hypersensitivity type of CholU in the old classification is assumed to be consistent with conventional CholU without angioedema and with sweat allergy among the four new subtypes, because these patients lack angioedema and anaphylaxis. In this subtype, certain satellite wheals that developed after the acetylcholine test were coincident with perspiration points [14] . Therefore, conventional sweat allergy-type CholU without angioedema could be associated with leakage of sweat from sweat ducts (Fig. 5 ) [9, 14] .
Follicular-type CholU with positive ASST result
This type of CholU is characterized by pinpoint wheals coincident with follicles. Wheals accompanied by aquagenic urticaria and follicular dermographism are also coincident with the follicles [56, 57] . Although the etiology of this urticaria has not been clarified, some authors have postulated that a water-soluble antigen located in the epidermis may cause mast cell degradation in patients with aquagenic urticaria, and that friction force may release unknown antigens from the bloodstream to trigger focal urticaria at sites of high-density mast cells, namely around follicles, in patients with follicular dermographism. A report describing a patient with both CholU and aquagenic urticaria suggests that these two diseases may be related. Notably, follicular-type CholU is mainly associated with a positive ASST result and lack of sweat allergy. With respect to the relationship between follicular wheals and serum factors, we assume that the existence of both serum factors and acetylcholine and/or particular antigens located in the epidermis can activate mast cells and induce focal urticaria around the follicles at sites of high-density mast cells (Fig. 5) .
CholU-PA with sweat allergy
Exercise-induced angioedema without a food trigger has been reported as an uncommon manifestation of CholU, although the causative allergen and clinical characteristics remain elusive. We recently reported a case series of patients with characteristic CholU-PA [13] , which was accompanied by angioedema around the eyelids and often anaphylaxis, and was closely related to atopic diathesis (14 of 15 patients) and female sex (all 15 patients). In addition, patients with CholU-PA had a high prevalence of sweat allergy (all 15 patients), whereas only four patients had a positive ASST result. Notably, wheals in these patients often appeared in lesions exhibiting an eczematous reaction consistent with atopic dermatitis. This implies that sweat leakage occurs easily in these lesions; this induces sensitization to sweat, and the subsequent sweat allergy induces an eczematous reaction and urticarial reaction in the lesions. Additionally, patients with CholU-PA respond poorly to H1RA therapy. Vadas et al. [8] recently described 19 patients with CholU with anaphylaxis as an under-recognized clinical entity. Similar to patients with CholU-PA, those with CholU with anaphylaxis showed a strong female predominance (78.9%; 15 of 19 patients), with moderate to severe reactions recurring about once per month. Although female prevalence is seen in patients with idiopathic anaphylaxis, severe multi-system reactions accompanying CholU can also easily develop in female patients.
CholU with acquired anhidrosis and/or hypohidrosis As described above, CholU is often accompanied by acquired anhidrosis and/or hypohidrosis. AIGA is an acquired disorder characterized by a reduced amount of sweat without a clear cause, and is associated with neither dysautonomia nor any neurological abnormalities other than sudomotor dysfunction. AIGA is assumed to be associated with three pathological conditions: sudomotor neuropathy, idiopathic pure sudomotor failure, and sweat gland failure [55] ; idiopathic pure sudomotor failure accounts for a large proportion of cases of AIGA. These pathological conditions are predominant in men and are likely to be complicated by pain, paresthesia, and CholU; however, psychogenic sweating is preserved. Because almost all patients with CholU who develop acquired anhidrosis and/or hypohidrosis are assumed to have AIGA, the comment on AIGA is explained as follows.
No epidemiological data on AIGA have been published to date; thus its prevalence and associated morbidity remain unknown. AIGA is assumed to be rare because only approximately 100 cases have been reported. However, patients with AIGA may be misdiagnosed, and a precise diagnosis may be achieved in only a small proportion of patients, given that the presence of AIGA is not well recognized. Indeed, the first case of AIGA in our facility was diagnosed and reported in 2009 [51] . Over the next 8 years, approximately 20 patients were newly diagnosed with AIGA (Fukunaga et al. unpublished data) , implying that more patients with AIGA may exist. Therefore, an epidemiological survey was conducted by a committee comprising members commissioned by the Japanese Dermatological Association, Japan Society of Neurovegetative Research, and Japanese Society for Perspiration Research [55] . In total, 145 cases of AIGA were identified among 94 departments of neurology or dermatology at Japanese university hospitals from 2010 through 2015. The incidence was significantly higher in men (126 men and 19 women), similar to a previous report. The inhibition of sweating, which is essential for body temperature regulation, results in discomfort, hyperthermia, nausea, vomiting, headache, and heat stroke. AIGA is frequently accompanied by CholU with symptoms of tingling, unpleasant sensations, and severe pruritus. We reported that untreated AIGA was associated with considerably reduced quality of life, greater than that with other skin diseases [16] .
As described above, decreased expression of CHRM3 in the sweat glands has been observed in patients with AIGA [5] . Reduced expression of acetylcholine esterase has been observed in patients with CholU with anhidrosis or hypohidrosis; their condition was equivalent to AIGA [15] . These findings suggest that excess acetylcholine stimulates sensory nerve terminals to produce pain and acts on CHRM3 in mast cells in the vicinity of sweat glands, causing wheals. Because some studies have revealed that few patients with AIGA exhibit sweat allergy, sweat allergy is not frequently associated with the pathogenesis of AIGA accompanied by CholU [12, 16] . A recent report showed that elevated serum carcinoembryonic antigen may be a marker of AIGA disease activity [58] .
The categorization and characteristics of the various subtypes of CholU described herein are illustrated in Table 1 .
Therapeutic management
The therapeutic approach to CholU differs largely based on the presence of sweating dysfunction. Differential diagnosis of subtypes based on the presence of sweating dysfunction is essential before treatment. However, very few previous works have focused on the therapeutic approach with respect to the presence of sweating dysfunction.
H1RAs are first-line therapy for patients with CholU, but many patients show only a mild to moderate response to standard H1RA doses [4, 41, 59] . Increasing the dose of an H1RA in patients with CholU that is refractory to standard doses may improve the disease activity, but this occurs in fewer than half of all patients [41] . The addition of an H2RA was reported to be effective in patients with refractory CholU that was unresponsive to up-dosing of an H1RA [4] . Other studies have demonstrated the efficacy of scopolamine butylbromide (an anticholinergic agent) [60] ; combinations of propranolol (a b2-adrenergic blocker), antihistamines, and montelukast [61] ; and treatment and injection with botulinum toxin [62] . High doses of danazol (600 mg daily) are also reportedly effective, but the side effect profile of danazol restricts its use [17] . Several studies have shown that omalizumab (a recombinant humanized IgG1 monoclonal antibody that binds to IgE) was effective for severe CholU [63, 64] , although a case of omalizumab treatment failure was also reported [65] . Desensitization protocols involving regular physical exercise and/or bathing or treatment with autologous sweat in patients with sweat allergy-type CholU have been described [9, 10, 43] .
In contrast, systemic administration of corticosteroids such as intravenous high-dose (500-1000 mg) steroid pulse therapy for AIGA appears to merit recommendation based on the findings presented in numerous case reports, despite an insufficient level of research-based evidence [16, 55, 66] . A trial of oral immunosuppressants is worthwhile in patients who do not respond to steroid pulse therapy [55] . In patients with AIGA, H1RAs can be administered at increased doses as appropriate for the symptoms experienced [67] . Topical application of keratolytic agents is reportedly effective in treating hypohidrotic CholU, which is associated with the occlusion of sweat ducts [50] .
These recommended therapeutic management approaches are summarized in Fig. 6 .
Conclusions
This review has presented the clinical features, provocation tests, and differential diagnoses of CholU. Four new pathogenesis-and/or clinical feature-based subtypes of CholU have been described and summarized. Although the underlying mechanism of CholU has not been fully clarified, the understanding of its pathological mechanism has gradually improved based on this subtype classification. Therapeutic management using this classification can lead to better control of treatment-resistant CholU. 
